Information
Platelet Glycoprotein IIb/IIIa Antagonists. An important advance in managing ischemic cardiovascular disease was the development of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors (now often replaced with newer therapies) (Table 30-5).